Experienced in Acute Monoblastic Leukemia (AmoL)

Dr. Matthew H. Carabasi

Oncology
925 Chestnut St, Suite 320a, 
Philadelphia, PA 
44 Years of Experience
Experienced in Acute Monoblastic Leukemia (AmoL)
925 Chestnut St, Suite 320a, 
Philadelphia, PA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Matthew Carabasi is an Oncologist in Philadelphia, Pennsylvania. Dr. Carabasi has been practicing medicine for over 44 years and is rated as an Experienced provider by MediFind in the treatment of Acute Monoblastic Leukemia (AmoL). His top areas of expertise are Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Acute Myeloblastic Leukemia without Maturation, and Multiple Myeloma.

His clinical research consists of co-authoring 21 peer reviewed articles and participating in 15 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has participated in 1 clinical trial in the study of Acute Monoblastic Leukemia (AmoL).

Specialties
Oncology
Licenses
Internal Medicine in PA
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO

Locations

925 Chestnut St, Suite 320a, Philadelphia, PA 19107

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

15 Clinical Trials

A Two-Step Approach to Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation for Advanced Cutaneous T Cell Lymphoma
A Two-Step Approach to Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation for Advanced Cutaneous T Cell Lymphoma
Enrollment Status: Withdrawn
Publish Date: May 02, 2025
Intervention Type: Drug, Radiation, Biological, Procedure
Study Phase: Phase 1
Phase I/II Study of Bendamustine in Combination With Ofatumumab, Carboplatin and Etoposide for Refractory or Relapsed Aggressive B-cell Lymphomas
Phase I/II Study of Bendamustine in Combination With Ofatumumab, Carboplatin and Etoposide for Refractory or Relapsed Aggressive B-cell Lymphomas
Enrollment Status: Completed
Publish Date: April 30, 2025
Intervention Type: Drug, Procedure, Genetic
Study Drugs: Bendamustine, Ofatumumab, Carboplatin, Etoposide
Study Phase: Phase 1/Phase 2
A Two Step Approach to Allogeneic Hematopoietic Stem Cell Transplantation for High-Risk Hematologic Malignancies Using One Haploidentical Donor
A Two Step Approach to Allogeneic Hematopoietic Stem Cell Transplantation for High-Risk Hematologic Malignancies Using One Haploidentical Donor
Enrollment Status: Completed
Publish Date: April 30, 2025
Intervention Type: Drug, Biological, Procedure, Radiation
Study Phase: Phase 2
A Two Step Approach To Matched-Sibling Allogeneic Hematopoietic Stem Cell Transplantation for High-Risk Hematological Malignancies
A Two Step Approach To Matched-Sibling Allogeneic Hematopoietic Stem Cell Transplantation for High-Risk Hematological Malignancies
Enrollment Status: Completed
Publish Date: April 30, 2025
Intervention Type: Device
Study Phase: Phase 2
A Pilot, Pharmacodynamic Correlate Trial of Sirolimus in Combination With Chemotherapy (Idarubicin, Cytarabine) for the Treatment of Newly Diagnosed Acute Myelogenous Leukemia
A Pilot, Pharmacodynamic Correlate Trial of Sirolimus in Combination With Chemotherapy (Idarubicin, Cytarabine) for the Treatment of Newly Diagnosed Acute Myelogenous Leukemia
Enrollment Status: Completed
Publish Date: April 29, 2025
Intervention Type: Drug
Study Phase: Early Phase 1
A Phase II Study of Azacitidine and Sirolimus for the Treatment of High Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia Refractory to or Not Eligible for Intensive Chemotherapy
A Phase II Study of Azacitidine and Sirolimus for the Treatment of High Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia Refractory to or Not Eligible for Intensive Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: April 25, 2025
Intervention Type: Drug
Study Drugs: Sirolimus, Azacitidine
Study Phase: Phase 2
A Two Step Approach to Non-Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Hematologic Malignancies
A Two Step Approach to Non-Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Hematologic Malignancies
Enrollment Status: Completed
Publish Date: April 24, 2025
Intervention Type: Drug, Radiation, Other, Biological, Procedure
Study Drugs: Fludarabine, T Cell-Depleted Donor Lymphocyte Infusion, Cyclophosphamide, Tacrolimus, Mycophenolate mofetil
Study Phase: Phase 2
A Phase 1 Dose Escalation Study To Assess Safety And Efficacy Of ADP-A2M4CD8 As Monotherapy Or In Combination With Either Nivolumab Or Pembrolizumab In HLA-A2+ Subjects With MAGE-A4 Positive Tumors (SURPASS)
A Phase 1 Dose Escalation Study To Assess Safety And Efficacy Of ADP-A2M4CD8 As Monotherapy Or In Combination With Either Nivolumab Or Pembrolizumab In HLA-A2+ Subjects With MAGE-A4 Positive Tumors (SURPASS)
Enrollment Status: Active_not_recruiting
Publish Date: March 13, 2025
Intervention Type: Genetic
Study Phase: Phase 1
A Screening Protocol to Determine Tumor Antigen Expression and HLA Sub-Type for Eligibility Determination for Clinical Trials Evaluating the Safety and Efficacy of Autologous T Cells Expressing Enhanced TCRs in Subjects With Solid and Hematological Malignancies
A Screening Protocol to Determine Tumor Antigen Expression and HLA Sub-Type for Eligibility Determination for Clinical Trials Evaluating the Safety and Efficacy of Autologous T Cells Expressing Enhanced TCRs in Subjects With Solid and Hematological Malignancies
Enrollment Status: Completed
Publish Date: March 04, 2025
A Phase 3, Randomized, Open-Label Study Evaluating the Efficacy of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Subjects With Relapsed/Refractory Diffuse Large B Cell Lymphoma (ZUMA-7)
A Phase 3, Randomized, Open-Label Study Evaluating the Efficacy of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Subjects With Relapsed/Refractory Diffuse Large B Cell Lymphoma (ZUMA-7)
Enrollment Status: Completed
Publish Date: December 24, 2024
Intervention Type: Biological, Drug
Study Drugs: Axicabtagene Ciloleucel, Platinum-containing salvage chemotherapy (eg, R-ICE) followed by high dose therapy (eg, BEAM) and autologous stem cell transplant in responders, Cyclophosphamide, Fludarabine
Study Phase: Phase 3
A Biomarker Validation Study to Establish Whether Serial Flow Cytometric Measurements Predict Clinical Response to Sirolimus and MEC (Mitoxantrone Etoposide Cytarabine) Treatment in Patients With High-Risk Acute Myelogenous Leukemia
A Biomarker Validation Study to Establish Whether Serial Flow Cytometric Measurements Predict Clinical Response to Sirolimus and MEC (Mitoxantrone Etoposide Cytarabine) Treatment in Patients With High-Risk Acute Myelogenous Leukemia
Enrollment Status: Completed
Publish Date: October 10, 2023
Intervention Type: Drug
Study Drugs: Sirolimus, Mitoxantrone, Etoposide, Cytarabine
Study Phase: Phase 2
A Phase 1 Open-Label, Multi-Center Study of PSMA Targeted Genetically Modified Chimeric Antigen Receptor T Cells in Patients With Metastatic Castration Resistant Prostate Cancer
A Phase 1 Open-Label, Multi-Center Study of PSMA Targeted Genetically Modified Chimeric Antigen Receptor T Cells in Patients With Metastatic Castration Resistant Prostate Cancer
Enrollment Status: Terminated
Publish Date: August 21, 2023
Intervention Type: Drug, Biological
Study Drugs: Cyclophosphamide, Fludarabine, Anakinra, Dual PSMA-Specific/TGFbeta-Resistant CAR-T Cells
Study Phase: Phase 1
A Two Step Approach to Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation for High Risk Hematologic Malignancies
A Two Step Approach to Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation for High Risk Hematologic Malignancies
Enrollment Status: Completed
Publish Date: January 06, 2023
Intervention Type: Drug, Radiation, Procedure, Other, Biological
Study Drugs: Fludarabine, Thiotepa, Cyclophosphamide, Tacrolimus, Mycophenolate Mofetil, Allogeneic Lymphocytes
Study Phase: Phase 2
Post Transplant Cyclophosphamide for Unrelated and Related Allogeneic Hematopoietic Stem Cell Transplantation for Hematological Malignancies
Post Transplant Cyclophosphamide for Unrelated and Related Allogeneic Hematopoietic Stem Cell Transplantation for Hematological Malignancies
Enrollment Status: Completed
Publish Date: December 21, 2022
Intervention Type: Drug, Radiation, Genetic
Study Phase: Phase 2
A Two Step Approach to Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Hematologic Malignancies
A Two Step Approach to Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Hematologic Malignancies
Enrollment Status: Completed
Publish Date: November 17, 2022
Intervention Type: Radiation, Drug, Biological, Device, Procedure
Study Drugs: Fludarabine, Busulfan, Cyclophosphamide, Tacrolimus, Mycophenolate Mofetil, Donor Lymphocyte Infusion
Study Phase: Phase 2
View 14 Less Clinical Trials

21 Total Publications

A prospective study of posttransplant cyclophosphamide for unrelated donor peripheral blood stem cell transplant with special attention to graft content and the impact of a higher γδ T cell dose.
A prospective study of posttransplant cyclophosphamide for unrelated donor peripheral blood stem cell transplant with special attention to graft content and the impact of a higher γδ T cell dose.
Journal: European journal of haematology
Published: October 15, 2023
Similar Doctors
Distinguished in Acute Monoblastic Leukemia (AmoL)
Dr. Dale G. Schaar
Oncology
Distinguished in Acute Monoblastic Leukemia (AmoL)
Dr. Dale G. Schaar
Oncology

Rutgers Health-Rwj Scleroderma Program

195 Little Albany St, 
New Brunswick, NJ 
 (53.1 miles away)
732-235-2465
Languages Spoken:
English
See accepted insurances

Dale Schaar is an Oncologist in New Brunswick, New Jersey. Dr. Schaar is rated as a Distinguished provider by MediFind in the treatment of Acute Monoblastic Leukemia (AmoL). His top areas of expertise are Myelodysplastic Syndrome (MDS), Acute Myeloid Leukemia (AML), Acute Myeloblastic Leukemia without Maturation, Acute Lymphoblastic Leukemia (ALL), and Bone Marrow Aspiration.

Advanced in Acute Monoblastic Leukemia (AmoL)
Dr. Margaret T. Kasner
Hematology Oncology | Hematology | Oncology
Advanced in Acute Monoblastic Leukemia (AmoL)
Dr. Margaret T. Kasner
Hematology Oncology | Hematology | Oncology

Jefferson University Physicians

925 Chestnut St, Suite 3, 
Philadelphia, PA 
 (0.1 miles away)
215-955-8874
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Margaret Kasner is a Hematologist Oncology specialist and a Hematologist in Philadelphia, Pennsylvania. Dr. Kasner is rated as a Distinguished provider by MediFind in the treatment of Acute Monoblastic Leukemia (AmoL). Her top areas of expertise are Acute Myeloid Leukemia (AML), Acute Myeloblastic Leukemia without Maturation, Myelodysplastic Syndrome (MDS), Bone Marrow Transplant, and Bone Marrow Aspiration.

Advanced in Acute Monoblastic Leukemia (AmoL)
Dr. Henry H. Fung
Hematology Oncology | Hematology | Oncology
Advanced in Acute Monoblastic Leukemia (AmoL)
Dr. Henry H. Fung
Hematology Oncology | Hematology | Oncology

Temple Faculty Practice Plan Inc

3401 N Broad St, 
Philadelphia, PA 
 (3.8 miles away)
215-707-5030
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Henry Fung is a Hematologist Oncology specialist and a Hematologist in Philadelphia, Pennsylvania. Dr. Fung is rated as a Distinguished provider by MediFind in the treatment of Acute Monoblastic Leukemia (AmoL). His top areas of expertise are Hodgkin Lymphoma, Classical Hodgkin Lymphoma, Large-Cell Immunoblastic Lymphoma, Bone Marrow Transplant, and Bone Marrow Aspiration.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Carabasi's expertise for a condition
ConditionClose
    View All 27 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile